
NCT00101712

1 Treatments

Studied treatment  vildagliptin 50 mg qd

Control treatment  placebo

Concomittant treatments  -

2 Patients

Patients  drug-naïve patients with type 2 diabetes and mild hyperglycaemia

Inclusion criteria  -

Exclusion criteria  -

3 Methods

Blinding  double-blind

Design  Parallel groups

Centers  -

Geographical area  -

Sizes  156/150

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>stroke</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>HbA1c goal &lt;7 all cause deaths</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>nephropathy</td>
<td>-/156</td>
<td>-/150</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV events</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV deaths</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>MI</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>all hypoglycemia</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Adverse events leading to treatment discontinuation</td>
<td>14/156</td>
<td>6/150</td>
<td>2.24</td>
<td>[0.84; 6.00]</td>
</tr>
</tbody>
</table>
5 References

Characterization of the influence of vildagliptin on model-assessed -cell function in patients with
10.1210/jc.2007-1639
Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Jauffret S, Foley JE Efficacy and
tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.
JE Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treat-
ment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008